Pharma BD Deal Intelligence

Gilead Sciences Inc. / Kite Pharma, Inc.

2017 · Acquisition/Merger · $11.9B · Complete

Neutral / mixed — critic reaction at announcement

CALLED IT — OFF BY 17

Gilead Sciences acquired Kite Pharma for approximately $11.9 billion ($180.00 per share in cash), establishing Gilead as a leader in CAR-T cell therapy with axicabtagene ciloleucel (later approved as Yescarta) for aggressive non-Hodgkin lymphoma.

Key facts

Announced Aug 28, 2017
Closed Oct 03, 2017
Deal value $11.9B
Deal type Acquisition/Merger
Therapeutic area Hematology, Oncology
Indications Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Primary Mediastinal B-Cell Lymphoma, Mantle Cell Lymphoma
Key assets axicabtagene ciloleucel (KTE-C19/Yescarta), KTE-585 (anti-BCMA CAR-T), KITE-718 (MAGE A3/A6 TCR), CAR-T manufacturing platform
Mechanism Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy

Related deals — scored

Deal	Year	Value	Outcome
Gilead Sciences Inc. / Kite Pharma, Inc. (this deal)	2017	$11.9B	67
Gilead Sciences Inc. / Pharmasset Inc.	2011	$11.2B	98
Gilead Sciences Inc. / Triangle Pharmaceuticals Inc.	2002	$464M	96
Gilead Sciences Inc. / CymaBay Therapeutics	2024	$4.4B	76
Gilead Sciences Inc. / Nurix Therapeutics Inc.	2019	$2.3B	69
Gilead Sciences Inc. / Immunomedics Inc.	2020	$21.0B	68
Gilead Sciences Inc. / Myogen Inc.	2006	$2.5B	62

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2017 deals · Gilead Sciences Inc. deals · Hematology deals